Login to Your Account

Clinic Roundup

Thursday, September 19, 2013
• Medivir AB, of Huddinge, Sweden, signed a license agreement with Grupo Ferrer International SA, of Barcelona, Spain, for commercialization of Adasuve (Staccato loxapine) in the Nordic region. Adasuve is approved in Europe for mild to moderate agitation of patients with schizophrenia or bipolar disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription